Protocol for Efficient Generation and Characterization of Adeno-Associated Viral Vectors

Human Gene Therapy Methods

Volumn 28, Issue 5, 2017, Pages 235-246

  Jungmann, Andreas ^a,b,d   Leuchs, Barbara ^c   Rommelaere, Jean ^c   Katus, Hugo A ^a,b   Müller, Oliver J ^a,b,d  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d UNIVERSITY OF KIEL   (Germany)

Author keywords

adeno associated virus (AAV); quality control; titration; vector purification; viral vector

Indexed keywords

ADENO ASSOCIATED VIRUS VECTOR; IODIXANOL;

ACCELERATION; ARTICLE; CELL LYSATE; CONTROLLED STUDY; DECELERATION; DOWNSTREAM PROCESSING; EMBRYO; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMIDITY; IN VITRO STUDY; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRECIPITATION; PRIORITY JOURNAL; PROCESS TECHNOLOGY; QUALITY CONTROL; SEROTYPE; SILVER STAINING; TARGET CELL; ULTRACENTRIFUGATION; VIRAL GENE DELIVERY SYSTEM; VIRUS CAPSID; VIRUS GENOME; VIRUS PURIFICATION; VIRUS TITRATION; ANALYSIS; CELL CULTURE TECHNIQUE; CENTRIFUGATION; DEPENDOPARVOVIRUS; GENETICS; HEK293 CELL LINE; METABOLISM; PLASMID; REAL TIME POLYMERASE CHAIN REACTION; STANDARDS;

CELL CULTURE TECHNIQUES; CENTRIFUGATION; DEPENDOVIRUS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HEK293 CELLS; HUMANS; PLASMIDS; QUALITY CONTROL; REAL-TIME POLYMERASE CHAIN REACTION; TRANSFECTION;

EID: 85032869168     PISSN: 19466536     EISSN: 19466544     Source Type: Journal    
DOI: 10.1089/hgtb.2017.192     Document Type: Article

References (35)

1. Cotmore, SF, Agbandje-McKenna, M, Chiorini, JA, et al. The family Parvoviridae. Arch Virol 2014;159:1239-1247.
2. Grimm, D, Kern, A, Rittner, K, et al. Novel tools for production and purification of recombinant adeno-associated virus vectors. Hum Gene Ther 1998;9:2745-2760.
3. Matsushita, T, Elliger, S, Elliger, C, et al. Adenoassociated virus vectors can be efficiently produced without helper virus. Gene Ther 1998;5: 938-945.
4. Xiao, X, Li, J, Samulski, RJ, Production of hightiter recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol 1998;72:2224-2232.
5. Sonntag, F, Köther, K, Schmidt, K, et al. The assembly-activating protein promotes capsid assembly of different adeno-associated virus serotypes. J Virol 2011;85:12686-12697.
6. Tratschin, JD, West, MH, Sandbank, T, et al. A human parvovirus, adeno-associated virus, as a eucaryotic vector: transient expression and encapsidation of the procaryotic gene for chloramphenicol acetyltransferase. Mol Cell Biol 1984;4:2072-2081.
7. Hermonat, PL, Muzyczka, N, Use of adenoassociated virus as a mammalian DNA cloning vector: transduction of neomycin resistance into mammalian tissue culture cells. Proc Natl Acad Sci U S A 1984;81:6466-6470.
8. Grimm, D, Kay, MA, Kleinschmidt, JA, Helper virusfree, optically controllable, and two-plasmid-based production of adeno-associated virus vectors of serotypes 1 to 6. Mol Ther 2003;7:839-850.
9. Booth, MJ, Mistry, A, Li, X, Thrasher, et al. Transfection-free and scalable recombinant AAV vector production using HSV/AAV hybrids. Gene Ther 2004;11:829-837.
10. Conway, JE, Rhys, CM, Zolotukhin, I, et al. Hightiter recombinant adeno-associated virus production utilizing a recombinant herpes simplex virus type I vector expressing AAV-2 Rep and Cap. Gene Ther 1999;6:986-993.
11. Hwang, KK, Mandell, T, Kintner, et al. High titer recombinant adeno-associated virus production using replication deficient herpes simplex viruses type 1. Mol Ther 2003;7:S14-S15.
12. Kang, W, Wang, L, Harrell, H, et al. An efficient rHSV-based complementation system for the production of multiple rAAV vector serotypes. Gene Ther 2009;16:229-239.
13. Thomas, DL, Wang, L, Niamke, J, et al. Scalable recombinant adeno-associated virus production using recombinant herpes simplex virus type 1 coinfection of suspension-adapted mammalian cells. Hum Gene Ther 2009;20:861-870.
14. Grieger, JC, Soltys, SM, Samulski, RJ. Production of recombinant adeno-associated virus vectors using suspension HEK293 cells and continuous harvest of vector from the culture media for GMP FIX and FLT1 clinical vector. Mol Ther 2016;24:287-297.
15. Negrete, A, Kotin, RM, Production of recombinant adeno-associated vectors using two bioreactor configurations at different scales. J Virol Methods 2007;145:155-161.
16. Negrete, A, Yang, LC, Mendez, AF, et al. Economized large-scale production of high yield of rAAV for gene therapy applications exploiting baculovirus expression system. J Gene Med 2007;9:938-948.
17. Negrete, A, Esteban, G, Kotin, RM, Process optimization of large-scale production of recombinant adeno-associated vectors using dielectric spectroscopy. Appl Microbiol Biotechnol 2007;76:761-772.
18. Gaudet, D, de WJ, Tremblay, K, et al. Review of the clinical development of alipogene tiparvovec genetherapy for lipoprotein lipase deficiency. Atheroscler Suppl 2010;11:55-60.
19. Franssen, R, Gaudet, D, Stroes, ES, et al. AAV1-LPLS447X gene therapy with alipogenetiparvovecprevents pancreatitis in lipoprotein lipase deficiency. Circulation 2009;120:S591-S592.
20. Carpentier, A, Frisch, F, Labbe, SM, et al. Gene therapy with alipogenetiparvovec results in enhancedpost-prandial clear ance of low density chylomicrons in LPLD patients. Circulation 2010;122(21 Suppl):A16900 [abstract].
21. Gaudet, D, Methot, J, Gagne, C, et al. Modificationsin triglyceride-rich lipoprotein metabolism inducedby alipogenetiparvovec (AAV1-LPLS447X GeneTherapy) correlate with clinical benefit in patientswith lipoprotein lipase deficiency (LPLD). Circulation 2010;122(21 Suppl.): A21355 [abstract].
22. Flotte, TR, Trapnell, BC, Humphries, et al. Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing a1-antitrypsin: interim results. Hum Gene Ther 2011;22:1239-1247.
23. Wang, XS, Ponnazhagan, S, Srivastava, A, Rescue and replication of adeno-associated virus type 2 as well as vector DNA sequences from recombinant plasmids containing deletions in the viral inverted terminal repeats: selective encapsidation of viral genomes in progeny virions. J Virol 1996;70:1668-1677.
24. Leuchs, B, Roscher, M, Müller, M, et al. Standardized large-scale H-1PV production process with efficient quality and quantity monitoring. J Virol Methods 2016;22948-22959.
25. Reed, SE, Staley, EM, Mayginnes, JP, et al. Transfection of mammalian cells using linear polyethylenimine is a simple and effective means of producing recombinant adeno-associated virus vectors. J Virol Methods 2006;138:85-98.
26. Dubielzig, R, King, JA, Weger, S, et al. Adenoassociated virus type 2 protein interactions: formation of pre-encapsidation complexes. J Virol 1999;73:8989-8998.
27. Gao, GP, Alvira, MR, Wang, L, et al. Novel adenoassociated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci U S A 2002;99:11854-11859.
28. Müller, OJ, Leuchs, B, Pleger, ST, et al. Improved cardiac gene transfer by transcriptional and transductional targeting of adeno-associated viral vectors. Cardiovasc Res 2006;70:70-78.
29. Wang, Z, Ma, HI, Li, J, et al. Rapid and highly efficient transduction by double-stranded adenoassociated virus vectors in vitro and in vivo. Gene Ther 2003;10:2105-2111.
30. Rapti, K, Louis-Jeune, V, Kohlbrenner, E, et al. Neutralizing antibodies against AAV serotypes 1, 2, 6, and 9 in sera of commonly used animal models. Mol Ther 2012;20:73-83.
31. Zolotukhin S, Byrne BJ, Mason E, et al. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther 1999;6:973-985.
32. Lock, M, McGorray, S, Auricchio, et al. Characterization of a recombinant adeno-associated virus type 2 Reference Standard Material. Hum Gene Ther 2010;21:1273-1285.
33. Hermens, WT, ter Brake, O, Dijkhuizen, et al. Purification of recombinant adeno-associated virus by iodixanol gradient ultracentrifugation allows rapid and reproducible preparation of vector stocks for gene transfer in the nervous system. Hum Gene Ther 1999;10:1885-1891.
34. U. S. Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research. Guidance for Industry: Potency Tests for Cellular and Gene Therapy Products. 2011. www. fda. gov/downloads/Biologics BloodVaccines/GuidanceComplianceRegulatory Information/Guidances/CellularandGeneTherapy/ UCM243392. pdf (Last accessed Aug 8, 2017).
35. Malyala, P, Singh, M. Endotoxin limits in formulations for preclinical research. J Pharm Sci 2008;97:2041-2044.